Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | FASN | P49327 | 7/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813666 | 0.90 | FASN (0.55) | ALBFASN | |
| SCHEMBL6834262 | 0.78 | ALB (0.58) | ALBFASN | |
| SCHEMBL6833057 | 0.78 | MEN1 (0.65) | ALBSMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL2274325 | 0.77 | HDAC2 (0.61) | MAPTSMN1; SMN2KCNQ3KCNQ2CYP1A2 | |
| SCHEMBL6349827 | 0.77 | ALB (1.00) | ALBALDH1A1 | |
| SCHEMBL6347749 | 0.76 | ALB (0.62) | ALBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24893406 | 0.76 | ADK (0.46) | PPARGFASNMAPTCYP1A2CYP2C19 | |
| SCHEMBL2272304 | 0.76 | NPC1 (0.55) | MAPTSMN1; SMN2KCNQ3KCNQ2CYP1A2 | |
| SCHEMBL24901393 | 0.76 | ADK (0.50) | PPARGFASNMAPTCYP1A2CYP2C19 | |
| SCHEMBL6359401 | 0.76 | ALB (0.63) | ALBMAPTLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885PPARG 285/4885FASN 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.